Osteoporosis and Dental Implant

Charite University, Berlin, Germany45 enrolled

Overview

The purpose of this study is to evaluate the influence of alendronate therapy on the wound healing after dental implants in patients with osteoporosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Osteoporosis

Interventions

alendronate once weekly 70mgDRUG

alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant

placeboDRUG

placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant

Eligibility

Sex: FEMALEMin age: 60 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women \> 2 years after menopause * Age between 60 and 75 years * Possibility to insert a dental implant * Osteoporosis as defined by WHO criteria (intervention group), or women without osteoporosis / osteopenia (non-intervention group) Exclusion Criteria: * Pathological findings in the jaw bone * Chronic inflammatory rheumatoid disease * Bisphosphonate treatments during the last 12 months * Inflammatory or metabolic bone disease, excluding osteoporosis * Systemic corticosteroid treatments of more than one month within previous 12 months * Severe diseases with life expectancy less than one year or expectation of rapid worsening within one year

Locations (1)

Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin

Berlin, Germany

RECRUITING

Outcomes

Primary Outcomes

Dental CT

Time frame: baseline, and 3,6,12 months after baseline

Central Contacts

Dieter Felsenberg, Prof. Dr.

CONTACT

+490384453046 dieter.felsenberg@charite.de

Hendrikje Boerst, Dipl. Wiss org.

CONTACT

+490384454745 hendrikje.boerst@charite.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.